Table 2 Factors that may affect the 6-month ORR.
Clinical features | Patients achieved OR (n = 57) | Patients not achieved OR (n = 25) | P value |
|---|---|---|---|
Median age (range), yrs | 64 (60–84) | 67 (60–75) | 0.266 |
Male/female (n) | 28/29 | 10/15 | 0.446 |
The median duration from diagnosis to treatment (days, range) | 1.3 (0.2–35.8) | 0.7 (0.3–30.7) | 0.281 |
Severity classification, no. (%) | 0.707 | ||
SAA | 47 (82.5%) | 19 (76%) | |
VSAA | 10 (17.5%) | 6 (24%) | |
HGB (g/L) | 59 (33–79) | 58 (25–82) | 0.503 |
PLT (×1012/L) | 9 (1–43) | 5 (1–20) | 0.007 |
WBC (×109/L) | 2.12 (0.74–4.04) | 1.81 (0.42–3.77) | 0.197 |
ANC (×109/L) | 0.62 (0.04–1.49) | 0.45 (0.04–0.96) | 0.030 |
Fer (μg/L) | 921.3 (11–6409) | 715 (321–4456.3) | 0.691 |
PNH clone–positive, no. (%) | 14 (24.6%) | 3 (12%) | 0.196 |
Chromosomal karyotype abnormality, no. (%) | 7(12.3%) | 4 (16%) | 0.918 |
Myeloid gene mutation, no. (%) | 16 (28.1%) | 6 (24%) | 0.702 |
Treatment, no. (%) | 0.472 | ||
ATG+CsA+AVA | 27 (47.4%) | 14 (56%) | |
CsA+AVA | 30 (52.6%) | 11 (44%) | |
3-month response, no. (%) | |||
ORR | 48 (84.2%) | 0 (0%) | 0.000 |
CRR | 4 (7.0%) | 0 (0%) | 0.423 |
